MinervaX is a biotechnology company focused on developing vaccines for infectious diseases. The company's lead candidate is a vaccine designed to prevent Group B Streptococcus (GBS) infections, which are a major cause of neonatal and maternal infections.

MinervaX

MinervaX is pursuing the development of a maternal vaccine for the prevention of adverse pregnancy outcomes and life-threating infections caused by Group B streptococcus (GBS). The vaccine is based on adjuvanted proteins antigens covering close to 100% of clinical GBS isolates.

Group B Streptococcal (GBS) is the leading cause of life-threatening infections in newborns.  Colonization of pregnant women with GBS may lead to adverse pregnancy outcomes such as late abortions, stillbirths, and preterm delivery.  Colonization may also lead to life-threatening infections in newborns for the first 3 months of life, causing pneumonia, septicemia and meningitis, which may lead to death or life-long disability.

Annually, GBS is responsible for some 320,000 cases of neonatal invasive disease, 60,000 stillbirths, 3,500,000 preterm deliveries, and 10,000 babies suffering from long-term neurological damage world-wide.


Minervax ApS

MinervaX is highlighted as one of six top companies at the forefront of the antibiotic resistance field 😀 

https://lnkd.in/dNicpRJN


Proud to share the news that MinervaX won Entrepreneur of the Year 2023 in the Life Science Category last night.

MinervaX Raises EUR 54M in Upsized Financing to Advance the Development of its Maternal Vaccine Against Group B Streptococcus 


Listen today to Chief Executive Officer, @Per Fischer as he discusses the Global Burden of Group B Streptococcus and @Minervax ApS's focus as it aims to address the issue with its novel, prophylactic GBS vaccine with Editor in Chief @Jim Cornall on @labiotech.eu's weekly 'Beyond Biotech' podcast.

Full podcast available below

#MinervaX has developed a novel, clinical #GBS pipeline which has the potential to reduce deaths associated with GBS across the population as it continues to tackle the urgent unmet medical need, worldwide. 

Learn more about MinervaX on www.minervax.com and its ongoing clinical trials.

#Biotech #maternalvaccine #adjuventedproteinsantigens #neonatalinvasivedisease #GroupBStreptococcus

Metric
Company Name	MinervaX
Symbol
MSH ID	COM:MINERVAX
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	DK
Stage
Employee Count	50
Website	minervax.com
LinkedIn	minervax-aps
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score	10.36
28-Day Growth Score	16.39
90-Day Growth Score	14.09
365-Day Growth Score	13.03

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:MINERVAX

MinervaX

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue